| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash provided by (used for) operating activities | ||||||||||||
Goodwill impairment charges | ||||||||||||
- | - | - | - | - | - | 423 | 4,350 | 697 | 1,817 | 0 | 2,613 | - |
Intangible asset impairment charges | ||||||||||||
105 | 35 | 4 | 11 | 19 | 195 | 53 | 142 | 21 | 65 | 12 | 177 | 21 |
Net loss (gain) on investments and notes receivable | ||||||||||||
-30 | 155 | -92 | -21 | -9 | 27 | -9 | 37 | 27 | -12 | 9 | 78 | 54 |
Contingent consideration expense (benefit) | ||||||||||||
-35 | -21 | -80 | 29 | 123 | -85 | 4 | -6 | 7 | 2 | 0 | - | - |
Payment of contingent consideration in excess of amount recognized at acquisition | ||||||||||||
6 | 9 | 14 | 57 | -57 | -103 | -5 | -8 | - | - | - | - | - |
Pension termination charges | ||||||||||||
- | - | - | - | 44 | 0 | 0 | - | - | - | - | - | - |
Inventory step-up amortization | ||||||||||||
46 | 6 | 10 | 22 | 36 | 9 | 0 | - | - | - | - | - | - |
Exchange (gain) loss | ||||||||||||
-358 | 11 | -15 | - | - | - | - | - | - | - | - | - | - |
Other, net | ||||||||||||
63 | 8 | 13 | -23 | 86 | 18 | 31 | -7 | -7 | 11 | -3 | 8 | 22 |
Increase (decrease) in operating assets and liabilities, net of acquisitions: | ||||||||||||
Trade accounts receivable | ||||||||||||
130 | 110 | 30 | 216 | 17 | -53 | 101 | -37 | -42 | -52 | -1 | -96 | -72 |
Other non-cash acquisition- and divestiture-related charges (credits) | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 250 | 568 |
Inventories | ||||||||||||
290 | 83 | 107 | -40 | -3 | 81 | 7 | -66 | 54 | 5 | 92 | 120 | -30 |
Other assets | ||||||||||||
-45 | 172 | 20 | 43 | -23 | 33 | -91 | 68 | 60 | -132 | -276 | 21 | -43 |
Accounts payable and accrued expenses | ||||||||||||
111 | -631 | 195 | 553 | -20 | 620 | -9 | -111 | -271 | -1,148 | 462 | 392 | 45 |
Other liabilities | ||||||||||||
-18 | -1,164 | 28 | -128 | 337 | 403 | 209 | 380 | 106 | -404 | 278 | -416 | 125 |
Cash provided by (used for) operating activities | ||||||||||||
1,836 | 310 | 1,426 | 1,182 | 691 | 1,269 | 1,110 | 1,280 | 1,008 | 325 | 835 | 1,216 | 934 |
Investing activities: | ||||||||||||
Purchases of property, plant and equipment | ||||||||||||
461 | 316 | 319 | 376 | 247 | 259 | 245 | 226 | 304 | 272 | 312 | 362 | 363 |
Proceeds from sale of property, plant and equipment | ||||||||||||
7 | 14 | 0 | 29 | 0 | 0 | 53 | 16 | 16 | 5 | 5 | 2 | 30 |
Payments for acquisitions of businesses, net of cash acquired | ||||||||||||
4,382 | 1,448 | 560 | 408 | 1,734 | 486 | 274 | 366 | 370 | 199 | 4 | 21 | 13 |
Proceeds from divestiture of certain businesses | ||||||||||||
90 | 0 | 0 | - | - | 12 | 30 | 10 | 1,440 | 0 | 0 | 1,287 | - |
Proceeds from royalty rights | ||||||||||||
52 | 0 | 0 | - | - | - | - | - | - | - | - | - | - |
Proceeds from Collection of Notes Receivable | ||||||||||||
- | - | - | - | 61 | -14 | -5 | -9 | -5 | -4 | -91 | 56 | 123 |
Payments for settlements of hedge contracts | ||||||||||||
199 | 0 | 0 | - | - | - | - | - | - | - | - | - | - |
Payments for investments and acquisitions of certain technologies | ||||||||||||
149 | 172 | 131 | 132 | 266 | 26 | 44 | 22 | 11 | 6 | 50 | - | - |
Proceeds from sales of investments and collections of notes receivable | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 149 | 243 |
Cash provided by (used for) investing activities | ||||||||||||
-5,041 | -1,921 | -1,010 | -887 | -2,186 | -745 | -475 | -579 | 776 | -468 | -793 | 324 | -474 |
Financing activities: | ||||||||||||
Payment of contingent consideration and royalty rights previously established in purchase accounting | ||||||||||||
135 | 19 | 33 | 65 | 156 | 34 | 160 | 146 | 7 | 12 | 523 | 675 | 248 |
Payments on short-term borrowings | ||||||||||||
1,000 | 0 | 0 | - | - | - | - | - | - | - | - | - | - |
Proceeds from royalty rights transfer | ||||||||||||
256 | 0 | 0 | - | - | - | - | - | - | - | - | - | - |
Proceeds from short-term borrowings, net of debt issuance costs | ||||||||||||
700 | 999 | 0 | - | - | - | - | - | - | - | - | - | - |
Net increase (decrease) in commercial paper | ||||||||||||
-575 | 21 | 1,183 | 0 | 0 | - | - | - | - | - | - | - | - |
Payments on borrowings from credit facilities | ||||||||||||
0 | 569 | 2,216 | 570 | 565 | 810 | 340 | 380 | 565 | 200 | 0 | 250 | 246 |
Proceeds from borrowings on credit facilities | ||||||||||||
0 | 569 | 2,156 | 630 | 565 | 810 | 340 | 371 | 565 | 200 | 0 | - | - |
Payments on long-term borrowings and debt extinguishment costs | ||||||||||||
3,560 | 602 | 1,000 | 250 | 1,150 | 0 | 1,450 | 10 | 1,250 | 1,500 | 2,825 | 1,175 | 1,000 |
Proceeds from long-term borrowings, net of debt issuance costs | ||||||||||||
7,229 | 987 | 0 | 0 | 2,535 | 0 | 1,440 | 0 | 0 | 973 | 1,972 | - | - |
Payments for acquisitions of treasury stock | ||||||||||||
- | - | - | - | - | 125 | 500 | 600 | 492 | 0 | 0 | - | - |
Cash used to net share settle employee equity awards | ||||||||||||
65 | 56 | 65 | 62 | 66 | 51 | -28 | -20 | - | - | - | - | - |
Proceeds from issuances of shares of common stock | ||||||||||||
123 | 101 | 85 | 111 | 114 | 60 | 74 | 21 | 21 | 31 | 33 | 71 | 132 |
Payments related to issuance of shares of common stock to Abbott Laboratories | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 60 |
Excess tax benefit relating to stock options | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 4 | 2 |
Cash provided by (used for) financing activities | ||||||||||||
2,973 | 1,432 | 110 | -206 | 1,276 | -150 | -624 | -764 | -1,728 | -508 | -820 | -1,350 | -680 |
Effect of foreign exchange rates on cash | ||||||||||||
10 | -8 | 4 | -2 | -4 | -4 | -1 | 3 | -2 | 0 | 1 | -1 | 4 |
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | ||||||||||||
-222 | -188 | 530 | 87 | -223 | 370 | 10 | -60 | 54 | -651 | -777 | 189 | -216 |
Supplemental Information | ||||||||||||
Net income (loss) | ||||||||||||
4,700 | 1,671 | 104 | 347 | -239 | -119 | -121 | -4,068 | 441 | -1,065 | -1,025 | -2,036 | -495 |
Adjustments to reconcile net income (loss) to cash provided by operating activities | ||||||||||||
Gain on sale of businesses | ||||||||||||
8 | 0 | 0 | - | - | 12 | 38 | 15 | 778 | 0 | 0 | - | - |
Depreciation and amortization | ||||||||||||
1,011 | 894 | 844 | 815 | 769 | 725 | 689 | 683 | 717 | 816 | 834 | 864 | 918 |
Purchased research and development | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 21 | 43 | 85 |
Gain on sale of property, plant and equipment | ||||||||||||
- | - | - | - | - | 0 | - | - | - | - | - | - | - |
Deferred and prepaid income taxes | ||||||||||||
-4,301 | -87 | 245 | -305 | -532 | -397 | -223 | -166 | 46 | -110 | -64 | -334 | -386 |
Stock-based compensation expense | ||||||||||||
157 | 140 | 127 | 116 | 107 | 103 | 105 | 108 | 128 | 150 | 144 | 138 | 122 |
Cash (received) paid for income taxes, net | ||||||||||||
242 | 1,037 | 42 | 94 | 80 | 74 | 67 | 97 | 138 | -286 | 46 | 416 | 475 |
Cash paid for interest | ||||||||||||
449 | 262 | 235 | 233 | 283 | 221 | 329 | 255 | 277 | 328 | 364 | 414 | 543 |
Fair value of contingent consideration recorded in purchase accounting | ||||||||||||
127 | 248 | 94 | 50 | 63 | 3 | 0 | 467 | 287 | 69 | 0 | - | - |
Stock and stock equivalents issued for acquisitions | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 90 |
Capital lease arrangements | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 31 |